In a report released today, Yuan Zhi from B.Riley Financial reiterated a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report), with a price target of $18.00. The company's shares closed yesterday at $11.05.According to TipRanks, Zhi is an analyst with an average return of -19.0% and a 20.83% success rate. Zhi covers the Healthcare sector, focusing on stocks such as IVERIC bio, Actinium Pharmaceuticals, and Lantheus.Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $32.50.See the top stocks recommended by analysts >>The company has a one-year high of $15.12 and a one-year low of $4.41.
https://www.tipranks.com/news/blurbs/actinium-pharmaceuticals-atnm-receives-a-buy-from-b-riley-financial-2?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2023 à Mar 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals